Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00846976 · ClinicalTrials.gov registry record · Phase 3
Treatment Protocol to Monitor the Safety of a 200 mg Dose of Bicalutamide in Patients With Advanced Prostate Cancer
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 101
- Enrollment target
NCT00846976 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 101 participants.
The verdict
NCT00846976, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 101 participants
- Enrollment target
Study Summary
This is an open label, single-centered treatment protocol designed to monitor the safety of patients treated with a 200 mg daily dose of CASODEX. Patient will receive CASODEX as long as physician feels that he is benefiting from this form of therapy.
Interventions
- DRUG Bicalutamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 1994-12 |
| Est. Completion | 2013-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00846976
The ClinicalTrials.gov registry entry for NCT00846976 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bicalutamide is the first listed.
NCT00846976 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00846976 about?
NCT00846976 is a clinical study titled "Treatment Protocol to Monitor the Safety of a 200 mg Dose of Bicalutamide in Patients With Advanced Prostate Cancer". This is an open label, single-centered treatment protocol designed to monitor the safety of patients treated with a 200 mg daily dose of CASODEX. Patient will receive CASODEX as long as physician feels that he is benefiting from this form of therapy.
What is the current status of trial NCT00846976?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 101 participants. The study started on 1994-12. Estimated completion is 2013-06.
What interventions are being tested in trial NCT00846976?
The interventions under investigation include: Bicalutamide (DRUG).
Who is sponsoring clinical trial NCT00846976?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.